“[The agency] is receiving significantly more combination products for review as technological advances continue to merge product types and blur the historical lines of separation” between devices and other types of therapeutic products.

FDA commissioner Andrew von Eschenbach, MD, discussing the ever-increasing workload of the FDA’s Office of Combination Products. “Combo product filings down in 2006, but filings more complex,” pp. 1, 6.